Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

A Randomized, Blinded, Positive-controlled Phase III Clinical Trial of Quadrivalent Influenza Vaccine (split Virion) in People Aged 3 Years and Above

This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above). Primary immunogenicity endpoints are the geometric mean titers, geometric mean fold increases, seropositive rates, and seroconversion rates of anti-influenza virus HI antibodies for all types 30 days after immunization, and primary safety endpoints are the occurrence of safety events after vaccination including the incidence of adverse events/adverse reactions within 30 minutes/7 days/30 days after immunization, as well as the incidence of serious adverse events/adverse relations within 6 months which will be defined as the secondary safety endpoint. Besides, the secondary endpoints are to evaluate the same index above in different administration programs in children aged 3-8 years.

Study Overview

• Status: Not yet recruiting
• Conditions: Influenza, Human; Influenza Viral Infections; Influenza B; Influenza, Human Prevention; Influenza a
• Intervention / Treatment: Biological: QIV; Biological: QIV Control

Detailed Description

This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety in 4400 subjects (aged 3 years and above). Then 1760 children (aged 3-8 years), 1320 adults/adolescents (aged 9-59 years), and 1320 elders (aged 60 years and above) are eligible for enrollment after assessing the medical history and physical examination.

1760 children's strata contains 1320 children with no history of influenza vaccine and 440 children with a history of influenza vaccine. Those 1320 children to the 2-dose vaccine, 1-dose vaccine, and control group in a ratio of 1:1:1, that is 440 subjects in the 2-dose vaccine cohort will receive 2 doses of experimental vaccines in a 0,28 program, and 440 subjects in the 1-dose vaccine or control cohort will receive 1 dose of experimental or active-controlled vaccine. The rest of the 440 children with a history of influenza vaccine will be randomly assigned to a 1-dose vaccine and control group in a ratio of 1:1, that is 220 subjects in the 1-dose vaccine or control cohort will receive 1 dose of experimental or active-controlled vaccine.

1320 adults/adolescents will be randomly assigned to a 1-dose vaccine and control group in a ratio of 1:1, that is 660 subjects in the 1-dose vaccine or control cohort will receive 1 dose of experimental or active-controlled vaccine.

1320 elders will be randomly assigned to a 1-dose vaccine and control group in a ratio of 1:1, that is 660 subjects in the 1-dose vaccine or control cohort will receive 1 dose of experimental or active-controlled vaccine.

The duration of intervention is no more than 1 month. With the 6-month safety monitoring after administration, the duration of the study is no more than 7 months.

For immunogenicity assessment, antibodies against all vaccine-related types of Influenza virus will be assessed in all subjects before vaccination and 30 days after full vaccination.

For safety assessment, the observation and evaluation of adverse events from Day 0 to Day 30 after each dose will be conducted by diary/contact cards and investigators' phone calls. Besides, the observation and evaluation of serious adverse events up to 6 months after vaccination will be conducted by active reports by subjects' legal guardians, or investigators' phone calls as well as face-to-face visits. Meanwhile, subjects will be observed at the site for at least 30 minutes after each dose.

For laboratory examination, urine routine tests or urine pregnancy tests (if applicable) will be performed on Day 0 before vaccination.

• Study Type: Interventional
• Enrollment (Estimated): 4400
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Guoyang Liao; Phone Number: +86 0871-68334483; Email: liaogy@imbcams.com.cn

Study Locations

• China
  • Guangxi
    • Guilin, Guangxi, China
      • Xing'an Center for Disease Control and Prevention
      • Contact: Bin He; Phone Number: +86 0773-6226818; Email: 13507837693@163.com
    • Guilin, Guangxi, China
      • Yangshuo Center for Disease Control and Prevention
      • Contact: Chunyuan Yang; Phone Number: +86 0773-8815366; Email: jkyangchunyuan@163.com
    • Nanning, Guangxi, China
      • Binyang Center for Disease Control and Prevention
      • Contact: Xiaoqin Gan; Phone Number: +86 0771-8250001; Email: byxgxq@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age Requirement: volunteers aged 3 years and above at the time of enrollment.
• Provision of Legal Identification: Volunteers and their legal guardians or appointed representatives must provide valid legal identification documents.
• Informed Consent: Volutters, legal guardians, or appointed representatives of volunteers must have the capacity to understand the informed consent document and the research process, voluntarily participate, sign the informed consent form, and be able to comply with the requirements in the study as well as complete relevant visits on time.
• Requirements for contraception: agree to take contraception actions in 6 months.
• Temperature Requirement: Axillary body temperature is less than 37.3°C.
• Previous Vaccination Requirements: (a) Received at least 1 dose of influenza vaccine within 1 year before screening in children aged 3-8 years; (b) Never received any influenza vaccine 1 year before screening in children aged over 3 years.

Exclusion Criteria:

Subjects meeting any of the following exclusion criteria will be not eligible for enrollment.

• Subjects with a history of severe allergy to egg or egg protein, such as those who have had symptoms such as angioedema, dyspnea, chest distress, or repeated vomiting due to eating eggs, and even those who have used epinephrine or other emergency medical treatment, especially those who have symptoms immediately or within a short period (minutes to hours).
• Subjects with influenza illness (clinically, serologically, or microbiologically confirmed) within 6 months before screening and enrollment.
• Have received an influenza vaccine within 1 year before enrollment or scheduled to receive another influenza vaccine during the study period.
• Allergic to any component contained in the investigational vaccine, or previous history of severe allergic to any vaccine or drug, such as anaphylactic shock, laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, local allergic necrosis reaction, dyspnea, angioedema, systemic rash and/or urticaria, etc.
• History of taking administration of a non-SARS-CoV-2 inactivated vaccine or subunit vaccine within 7 days before enrollment, or any live attenuated vaccine or SARS-CoV-2 vaccine within 14 days before enrollment, or subjects have scheduled to receive another vaccine within 1 month after receipt of the investigational vaccine
• Subjects with convulsion, epilepsy, encephalopathy (such as moderate to severe hypoxic-ischemic encephalopathy, intracranial hemorrhage, cerebral palsy, intracranial tumor, cerebral infarction, stroke, intracranial infection, etc.), psychiatric history or family history
• Have been diagnosed with a serious medical condition or congenital malformation that may interfere with the conduct or completion of the study (including but not limited to suffering from respiratory diseases such as asthma or during episodes of chronic bronchitis, Down syndrome, thalassemia, heart disease, severe cardiac arrhythmias, kidney disease, diabetes (diabetics with poor glycemic control or severe complications), autoimmune diseases, genetic allergies, Guillain-Barre syndrome, Crohn disease, malignancies, severe infectious/allergic skin diseases, etc.)
• Adults aged 18 years or older with medically uncontrolled abnormal blood pressure (systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg or systolic blood pressure ≤ 90mmHg and/or diastolic blood pressure ≤ 60 mmHg)
• Subjects with acute illness or in the acute phase of a chronic illness within 3 days before vaccination
• Subjects with fever (axillary temperature ≥37.3 ° C) within 3 days before vaccination or use of antipyretic, analgesic, or antiallergic medications
• Subjects with a hereditary bleeding tendency or coagulopathy, or a history of bleeding disorders
• Have received a blood transfusion or use of blood products within 3 months before enrollment, or planned to do so within 1 month after full immunization
• History of surgical removal of the spleen or other vital organs for any reason
• Use of any investigational or unregistered product (drug, vaccine, biological product, or device) other than a study vaccine within 3 months before enrollment or planned for use during the study
• Have treatment with immunosuppressive agents within 6 months before enrollment, such as long-term systemic glucocorticoid therapy (e.g., prednisone or a similar drug for more than 2 consecutive weeks within 6 months), but topical use (e.g., ointments, eye drops, inhalers, or nasal sprays) was allowed. Topical use should not exceed the recommended dose on the label or have any signs of systemic exposure
• Have been diagnosed with an infectious disease that may interfere with the conduct or completion of the study, such as active tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, etc
• Being lactating, pregnant (including a positive urine pregnancy test), or planning to become pregnant within 6 months of vaccination
• Subjects plan to move out of the local area before the end of the study or leave the local area for an extended period during the scheduled study visit
• Subjects with abnormal vital signs with clinical significance
• Investigators' Discretion: The final exclusion criterion is the discretion of investigators to determine whether a subject is suitable for participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention (Elders aged 60 years and above, one-dose); QIV in elders aged 60 years and above on Day 0	Biological: QIV; Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
Active Comparator: Control (Elders aged 60 years and above, one-dose); Control vaccine in elders aged 60 years and above on Day 0	Biological: QIV Control; Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
Experimental: Intervention (Children aged 3-8 years, two-dose); QIV in children aged 3-8 years on Day 0 and Day 28	Biological: QIV; Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
Experimental: Intervention (Children aged 3-8 years, one-dose); QIV in children aged 3-8 years on Day 0	Biological: QIV; Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
Active Comparator: Control (Children aged 3-8 years, one-dose); Control vaccine n children aged 3-8 years on Day 0	Biological: QIV Control; Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose
Experimental: Intervention (Aged 9-59 years, one-dose); QIV in adults and adolescents aged 9-59 years on Day 0	Biological: QIV; Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose
Active Comparator: Control (Aged 9-59 years, one-dose); Control Vaccine in adults and adolescents aged 9-59 years on Day 0	Biological: QIV Control; Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety index - incidence of adverse events/adverse reactions	Incidence of adverse events/adverse reactions after the first dose vaccination	Day 0 to 7 after the first dose vaccination
Safety index - incidence of adverse events/adverse reactions	Incidence of adverse events/adverse reactions after the second dose vaccination (applicable for the two-dose children cohort)	Day 0 to 7 after the second dose vaccination
Immunogenicity index - seroconversion rates of HI antibody against all types	Antibody assay will be performed using the hemagglutination inhibition test. Seroconversion will be defined as a change from seronegative (Antibody titers<1:40) to seropositive (Antibody titers≥1:40), or a ≥4-fold increase from baseline.	Between baseline and Day 30 after full vaccination
Immunogenicity index - Seropositive rates of HI antibody against all types	Antibody assay will be performed using the hemagglutination inhibition test. Seropositive is defined as antibody titers≥1:40	Day 30 after full vaccination
Immunogenicity index - geometric mean titer (GMT) of HI antibody against all types	Antibody assay will be performed using the hemagglutination inhibition test.	Day 30 after full vaccination
Safety index - incidence of adverse events/adverse reactions	Incidence of adverse events/adverse reactions after full vaccination	From Day 0 to Day 30 after full vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety index - incidence of serious adverse events/adverse reactions	Incidence of serious adverse events/adverse reactions after vaccination	From the beginning of the vaccination up to 6 months after the last vaccination completed
Immunogenicity index - seroconversion rates of HI antibody against all types	Antibody assay will be performed using the hemagglutination inhibition test. Seroconversion will be defined as a change from seronegative (Antibody titers<1:40) to seropositive (Antibody titers≥1:40), or a ≥4-fold increase from baseline. (Applicable for susceptible cohort)	Between baseline and Day 30 after full vaccination
Immunogenicity index - Seropositive rates of HI antibody against all types	Antibody assay will be performed using the hemagglutination inhibition test. Seropositive is defined as antibody titers≥1:40 (Applicable for susceptible cohort)	Day 30 after full vaccination
Immunogenicity index - geometric mean titer (GMT) of HI antibody against all types	Antibody assay will be performed using the hemagglutination inhibition test. (Applicable for susceptible cohort)	Day 30 after full vaccination

Collaborators and Investigators

• Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences
• Collaborators: Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
• Investigators: Principal Investigator: Teng Huang, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control

Study record dates

Study Major Dates

• Study Start (Estimated): February 8, 2025
• Primary Completion (Estimated): July 15, 2025
• Study Completion (Estimated): October 15, 2025

Study Registration Dates

• First Submitted: January 24, 2025
• First Submitted That Met QC Criteria: January 24, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 24, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Respiratory Tract Diseases; Influenza, Human; Virus Diseases
• Other Study ID Numbers: 20221201_3

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No